Literature DB >> 33462738

Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.

Naoko Sasamoto1,2, Allison F Vitonis3, Raina N Fichorova4,5, Hidemi S Yamamoto5, Kathryn L Terry3,4,6, Daniel W Cramer3,4,6.   

Abstract

PURPOSE: Among healthy postmenopausal women, levels of CA125 and CA15.3 are influenced by demographic and reproductive factors, including race/ethnicity. In this study, we sought to examine the interaction between race/ethnicity and other correlates of these biomarkers and whether the racial differences observed are simply determined by other correlates with racial differences.
METHODS: In archived sera from 946 postmenopausal women who participated in the 2001-2002 cycle of the National Health and Nutrition Examination Survey, we measured CA125 and CA15.3 and examined their associations with health survey and examination data available in this cohort. We used multivariable linear regression to examine the association between CA125 and CA15.3 and race/ethnicity. We then calculated geometric means of these markers by demographic and reproductive factors stratified by race/ethnicity and used likelihood ratio tests to evaluate heterogeneity.
RESULTS: Non-white race was associated with lower CA125, with Non-Hispanic Black women being associated with - 29.0% (95% CI - 42.5%, - 12.2%) difference and Mexican American women being associated with - 6.4% (95% CI - 18.1%, 6.9%) difference on average compared to Non-Hispanic White women. Associations between CA125 and age and parity varied by race/ethnicity. Non-Hispanic Black women were associated with higher CA15.3 compared to Non-Hispanic White women, with 17.3% (95% CI - 0.5%, 38.3%) differences on average. Associations between CA15.3 and age, number of births, and age at natural menopause varied by race/ethnicity.
CONCLUSIONS: Among postmenopausal women, Non-Hispanic Black women were associated with lower CA125 and higher CA15.3 levels compared to Non-Hispanic White women. Our results support that race/ethnicity should be considered when assigning thresholds for these biomarkers being tested for diagnostic or screening purposes.

Entities:  

Keywords:  CA125; CA15.3; Postmenopausal; Racial/ethnic difference

Mesh:

Substances:

Year:  2021        PMID: 33462738      PMCID: PMC7887701          DOI: 10.1007/s10552-020-01384-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  21 in total

1.  The National Health and Nutrition Examination Survey: Sample Design, 1999-2006.

Authors:  Lester R Curtin; Leyla K Mohadjer; Sylvia M Dohrmann; Jill M Montaquila; Deanna Kruszan-Moran; Lisa B Mirel; Margaret D Carroll; Rosemarie Hirsch; Susan Schober; Clifford L Johnson
Journal:  Vital Health Stat 2       Date:  2012-05

2.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

3.  Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.

Authors:  Lauren C Peres; Harvey Risch; Kathryn L Terry; Penelope M Webb; Marc T Goodman; Anna H Wu; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Ani Manichaikul; Sarah E Abbott; Fabian Camacho; Susan J Jordan; Christina M Nagle; Mary Anne Rossing; Jennifer A Doherty; Francesmary Modugno; Kirsten Moysich; Roberta Ness; Andrew Berchuck; Linda Cook; Nhu Le; Angela Brooks-Wilson; Weiva Sieh; Alice Whittemore; Valerie McGuire; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Chiuchen Tseng; Malcom Pike; Joellen M Schildkraut
Journal:  Int J Epidemiol       Date:  2018-06-01       Impact factor: 7.196

4.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

Authors:  I Jacobs; D Oram; J Fairbanks; J Turner; C Frost; J G Grudzinskas
Journal:  Br J Obstet Gynaecol       Date:  1990-10

5.  A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Authors:  Claire S Zhu; Paul F Pinsky; Daniel W Cramer; David F Ransohoff; Patricia Hartge; Ruth M Pfeiffer; Nicole Urban; Gil Mor; Robert C Bast; Lee E Moore; Anna E Lokshin; Martin W McIntosh; Steven J Skates; Allison Vitonis; Zhen Zhang; David C Ward; James T Symanowski; Aleksey Lomakin; Eric T Fung; Patrick M Sluss; Nathalie Scholler; Karen H Lu; Adele M Marrangoni; Christos Patriotis; Sudhir Srivastava; Saundra S Buys; Christine D Berg
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

6.  Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Authors:  Daniel W Cramer; Robert C Bast; Christine D Berg; Eleftherios P Diamandis; Andrew K Godwin; Patricia Hartge; Anna E Lokshin; Karen H Lu; Martin W McIntosh; Gil Mor; Christos Patriotis; Paul F Pinsky; Mark D Thornquist; Nathalie Scholler; Steven J Skates; Patrick M Sluss; Sudhir Srivastava; David C Ward; Zhen Zhang; Claire S Zhu; Nicole Urban
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

Review 7.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

8.  Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.

Authors:  G G Bon; P Kenemans; R Verstraeten; G J van Kamp; J Hilgers
Journal:  Am J Obstet Gynecol       Date:  1996-01       Impact factor: 8.661

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

10.  Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.

Authors:  Renée T Fortner; Allison F Vitonis; Helena Schock; Anika Hüsing; Theron Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Giuseppe Matullo; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; Elisabete Weiderpass; Inger Torhild Gram; Mie Jareid; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; María Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Jenny Brändstedt; Annika Idahl; Kay-Tee Khaw; Naomi Allen; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Daniel W Cramer; Rudolf Kaaks; Kathryn L Terry
Journal:  J Ovarian Res       Date:  2017-03-20       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.